Accueil   Diary - News   All news Poxel Successfully Raises €17.7 Million in a Capital Increase and Announces Program Update and Preclinical Results on PXL770

Poxel Successfully Raises €17.7 Million in a Capital Increase and Announces Program Update and Preclinical Results on PXL770

Poxel Successfully Raises €17.7 Million in a Capital Increase

 

LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) (“Poxel”, or the “Company”), today announced the successful private placement of 2,358,483 new ordinary shares, each with a nominal value of €0.02 per share (the “New Shares”), reserved to a specified category of investors (the “Reserved Offering”). The gross proceeds of the Reserved Offering are €17,688,622.50 ($19.4 million).

 

Read the press release

 

Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

 

LYON, France--(BUSINESS WIRE)-- POXEL SA, today announced new preclinical results for PXL770, the lead molecule in the Company’s adenosine monophosphate-activated protein kinase (AMPK) platform. PXL770, a directAMPK activator, was evaluated in a rodent NASH model in combination with other key agents in development, including an FXR agonist (obeticholic acid), a GLP-1 receptor agonist (semaglutide) and a thyroid receptor β agonist (MGL-3196). The results highlight PXL770 as a potentially novel NASH therapy that may also produce complementary benefits when combined with other agents with different mechanisms of action.

 

Read the press release